Phathom Pharmaceuticals PHAT Cash Flow Statement (2018-2026)

NASDAQ PHAT
$9.47 +0.42 (+4.64%)
As of: Sep 4, 2026 · 3:58 PM EDT
Reported Financials

Phathom Pharmaceuticals Quarterly Cash Flow Statement

Periods 32 quarters
Latest Jun 2026

Phathom Pharmaceuticals reported cash from operations of -$1.93M and free cash flow of -$1.93M for the quarter ended Jun 2026, up 96.9% year over year. This cash flow statement covers 32 quarters of results from Sep 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-34.61M-35.81M-40.66M-50.92M-51.08M-54.96M-37.83M-40.97M-43.05M-79.56M-82.81M-91.44M-85.57M-74.50M-94.29M-75.66M-29.97M-21.14M-29.54M-17.56M
Share-based CompensationStock Comp.
4.42M4.34M5.78M5.88M5.82M6.66M7.05M7.25M6.14M24.58M6.26M6.54M6.45M6.69M7.05M9.67M18.80M5.61M20.10M18.10M
Gains from Investment SecuritiesGains Investment
Asset Writedowns and ImpairmentWritedown
0.24M0.47M0.12M0.90M-0.08M-0.54M
Cash from OperationsCash from Ops.
-29.07M-41.26M-44.76M-25.72M-35.02M-41.04M-39.67M-22.20M-31.91M-43.80M-69.02M-70.72M-63.57M-63.46M-84.93M-62.73M-14.12M-5.00M-15.65M-1.93M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
2.39M0.51M0.52M0.53M0.56M0.50M0.50M0.27M0.54M0.57M0.47M0.50M0.59M0.63M0.70M0.73M0.78M0.81M0.84M0.91M
Depreciation & Amortization (CF)Dep. & Amort.
0.13M0.14M0.13M0.15M0.17M0.17M0.15M0.12M0.12M0.18M0.21M0.20M0.19M0.19M0.18M0.17M0.16M0.13M0.11M0.11M
Change in Working Capital
Change in ReceivablesChange Receivables
1.64M2.24M7.00M10.18M17.75M-2.43M14.89M4.53M22.34M2.60M16.70M
Change in InventoryChange Inventory
0.11M9.33M0.42M-0.27M0.42M5.58M12.33M1.85M-0.40M-2.00M-0.67M3.96M
Change in Accured ExpensesChange Accured Exp.
3.23M-0.16M-6.08M8.94M1.90M3.92M-11.30M2.86M4.59M10.27M-5.01M8.69M11.32M19.94M-6.96M12.38M1.11M27.57M-3.12M23.40M
Investing Activities
Capital ExpendituresCapex
0.01M0.10M0.12M0.38M0.13M0.41M0.21M0.01M3.23M-1.82M0.04M0.05M0.04M0.01M0.04M0.07M0.03M1.08M0.17M
Cash from Investing ActivitiesCash from Investing
-0.01M-0.10M-0.07M-0.43M-0.13M-0.41M-0.21M-0.01M-0.94M-0.47M-0.04M-0.05M-0.04M-0.01M-0.02M-0.10M-0.03M-0.09M-0.06M-0.04M
Financing Activities
Other financing activitiesOther financing
1.26M0.16M0.01M172.58M0.28M1.30M0.08M0.29M1.26M0.59M3.55M
Cash from Financing ActivitiesCash from Financing
44.03M0.16M24.60M14.07M141.50M0.01M211.99M9.90M24.77M122.06M26.05M0.08M-0.27M-0.10M66.64M3.55M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
1.73M1.24M1.74M1.04M2.49M1.87M2.28M0.95M4.82M0.34M
Net Equity Issued and RepurchasedNet Equity Issued
24.60M14.07M0.00M38.70M
Additional items
Change in Cash
14.95M-41.20M-44.82M69.30M-10.55M-41.45M-25.81M119.30M-32.84M167.72M-59.16M-46.00M58.44M-37.41M-84.95M-62.75M-14.41M-5.18M50.93M1.58M
Free Cash FlowFCF
-29.08M-41.36M-44.88M-26.09M-35.15M-41.45M-39.88M-22.21M-35.14M-41.98M-69.06M-70.77M-63.62M-63.46M-84.97M-62.80M-14.14M-6.08M-15.82M-1.93M
Net Cash FlowNCF
14.95M-41.20M-44.82M-26.14M-10.55M-41.45M-25.81M119.30M-32.84M167.72M-59.16M-46.00M58.44M-37.41M-84.95M-62.75M-14.41M-5.18M50.93M1.58M